Filing Details
- Accession Number:
- 0001209191-21-017020
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-03 17:10:54
- Reporting Period:
- 2021-03-01
- Accepted Time:
- 2021-03-03 17:10:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1623526 | Stoke Therapeutics Inc. | STOK | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1181556 | A Arthur Levin | C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-01 | 2,776 | $0.40 | 2,776 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-03-01 | 1,842 | $0.40 | 4,618 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-03-01 | 7,882 | $0.60 | 12,500 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-03-01 | 7,543 | $60.55 | 4,957 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-03-01 | 4,957 | $61.14 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Director Stock Option (Right to Buy) | Disposition | 2021-03-01 | 2,776 | $0.00 | 2,776 | $0.40 |
Common Stock | Director Stock Option (Right to Buy) | Disposition | 2021-03-01 | 1,842 | $0.00 | 1,842 | $0.40 |
Common Stock | Director Stock Option (Right to Buy) | Disposition | 2021-03-01 | 7,882 | $0.00 | 7,882 | $0.60 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2026-02-11 | No | 4 | M | Direct | |
0 | 2027-02-02 | No | 4 | M | Direct | |
8,764 | 2028-04-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 17,979 | Indirect | Arthur A. Levin, Ph.D., Trustee, Butler-Levin Revocable Trust |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.89 to $60.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option is 100% vested and exercisable.
- The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date.